Vigonvita Life Sciences Co (HKSE:02630) ROCE %: -59.47% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02630 Vigonvita Life Sciences Co Ltd HKSE:02630
8 GF Score
Price HK$90.00
! 2 Warning Signs
View Full Analysis

What is Vigonvita Life Sciences Co ROCE %?

Vigonvita Life Sciences Co HKSE:02630 +5.32% 8 ROCE % is -59.47% as of Dec. 2025. GuruFocus rates HKSE:02630 with a GF Score™ of 8/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vigonvita Life Sciences Co's annualized ROCE % for the quarter that ended in Dec. 2025 was -59.47%.

Vigonvita Life Sciences Co  (HKSE:02630) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vigonvita Life Sciences Co ROCE % Related Terms

Vigonvita Life Sciences Co ROCE % Historical Data

* Premium members only.

The historical data trend for Vigonvita Life Sciences Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vigonvita Life Sciences Co ROCE % Chart

Vigonvita Life Sciences Co Annual Data
Trend Dec23 Dec24 Dec25
ROCE %
3.49 -50.13 -59.47

Vigonvita Life Sciences Co Semi-Annual Data
Dec23 Dec24 Dec25
ROCE % 3.49 -50.13 -59.47
HKSE:02630
8GF Score
Vigonvita Life Sciences Co Ltd HKSE:02630
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vigonvita Life Sciences Co ROCE % Calculation

Vigonvita Life Sciences Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-379.524/( ( (775.083 - 343.999) + (1424.348 - 579.125) )/ 2 )
=-379.524/( (431.084+845.223)/ 2 )
=-379.524/638.1535
=-59.47 %

Vigonvita Life Sciences Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Dec. 2024 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Dec. 2024 )(Q: Dec. 2025 )
=-379.524/( ( (775.083 - 343.999) + (1424.348 - 579.125) )/ 2 )
=-379.524/( ( 431.084 + 845.223 )/ 2 )
=-379.524/638.1535
=-59.47 %

(1) Note: The EBIT data used here is one times the annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -59.47% mean?
Vigonvita Life Sciences Co (HKSE:02630) has a ROCE % of -59.47% as of Dec. 2025.
Is Vigonvita Life Sciences Co's ROCE % too high?
Vigonvita Life Sciences Co's current ROCE % is -59.47%. Overall, Vigonvita Life Sciences Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Vigonvita Life Sciences Co's ROCE % compare to LLY and JNJ?
Vigonvita Life Sciences Co's ROCE % of -59.47% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.06, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vigonvita Life Sciences Co's current ROCE % is -59.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vigonvita Life Sciences Co stock overvalued right now?
Vigonvita Life Sciences Co (HKSE:02630) has a current ROCE % of -59.47%. The current ROCE % is -59.47%. Vigonvita Life Sciences Co's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Vigonvita Life Sciences Co (HKSE:02630), the current ROCE % is -59.47% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vigonvita Life Sciences Co Business Description

Address No. 108, Yuxin Road, 8th Floor, Building A, Suzhou Industrial Park District, Suzhou, CHN, 215123
Vigonvita Life Sciences Co Ltd biopharmaceutical company. It is focused on innovation driven biopharmaceutical development, with a strategic emphasis on addressing unmet clinical needs in the treatment of neuropsychiatric, infectious, and andrological diseases. The company's core Products include LV232, anti-depression drug candidate, VV913: a novel investigational drug candidate for premature ejaculation and, VV116: an oral nucleoside analog with broad-spectrum antiviral potential. The company's operations are located in the PRC and Uzbekistan. Revenue is generated from the out-licensing and the sales of its pharmaceutical products.
8GF Score

Get the complete analysis for HKSE:02630

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$90.00
Price